Paul Nouri's questions to Trinity Biotech PLC (TRIB) leadership • Q3 2024
Question
Paul Nouri of Noble Equity Funds asked for clarification on the top 2-3 drivers for achieving the Q2 2025 revenue and EBITDASO targets, whether future TrinScreen revenue would depend on new or existing tenders, and the remaining capacity on the company's At-The-Market (ATM) offering.
Answer
President and CEO John Gillard identified the primary drivers for reaching the 2025 financial targets as the consolidation of U.S. manufacturing facilities from three to one and the offshoring of less complex manufacturing operations, which significantly reduces overhead. He stated that 2025 TrinScreen revenue is expected to be a mix of existing business and new tender wins, acknowledging the inherent uncertainty in the timing of new government contracts. Gillard also confirmed that less than $1 million in capacity remained on the current ATM filing.